Optimal Patient Adherence and Long-Term Treatment Outcomes of Neovascular Age-Related Macular Degeneration in Real-Life
Authors:
- 7 April 2022
- journal article
- research article
- Published by Taylor & Francis in Current Eye Research
- Vol. 47 (6) , 889-896
Abstract
To report on long-term real-life outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy in neovascular age-related macular degeneration (nAMD) with optimal patient adherence. For this retrospective monocenter study, we identified 3217 eyes of 2793 patients that received a minimum of three intravitreal anti-VEGF injections for nAMD therapy between 2006 and 2014 at the University Eye Hospital Munich. From those, we included eyes with treatment-naïve nAMD, follow-up (FU) of ≥60 months and continuous adherence during FU. Primary measures were corrected visual acuity (VA), number of injections and visits as well as treatment regimen. We included 161 eyes of 125 patients with a mean FU of 8.0 ± 2.3 years. Mean VA at baseline was 60.1 letters (Snellen equivalent, 20/63). After the third year, mean VA declined constantly by 2-3 letters per year. After 5 and 8 years, 26.1% and 42.1% had lost at least 3 lines from baseline. Mean cumulative number of injections was 5.3 after the first year, and 23.9, 38.1, 48.5 after 5, 8, and 10 years. ‘Treat and extent’ regimen with higher injection frequency correlated with better function. At time of last FU, 69.8% of eyes were under active treatment. Eyes with ≥70 letters at baseline correlated with better VA at the end of FU. Despite optimal patient adherence, visual function declined progressively in real-life nAMD therapy over long-term. The highest impact on treatment success is given by an early treatment start with individual but intensive anti-VEGF therapy.Keywords
This publication has 25 references indexed in Scilit:
- Makula-Atrophie bei feuchter altersabhängiger MakuladegenerationDer Ophthalmologe, 2016
- Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study)Ophthalmology, 2016
- Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA studyEye, 2016
- International vision requirements for driver licensing and disability pensions: using a milestone approach in characterization of progressive eye diseaseClinical Ophthalmology, 2010
- LONG-TERM FOLLOW-UP FOR TYPE 1 (SUBRETINAL PIGMENT EPITHELIUM) NEOVASCULARIZATION USING A MODIFIED “TREAT AND EXTEND” DOSING REGIMEN OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPYRetina, 2010
- Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trialsBritish Journal of Ophthalmology, 2009
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- The Natural History and Prognosis of Neovascular Age-Related Macular DegenerationOphthalmology, 2008
- Ranibizumab According to Need: A Treatment for Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006